Work

P186 From late diagnosis and palliation to early detection and cure: the sustained impact of a lung cancer screening programme

Year: 2026
Type: conference-abstract
Abstract: Introduction and Objectives Our hospital trust serves a population of around 445,000 people with high level of social deprivation, smoking prevalence, lung cancer incidence and mortality. In 2018, the area recorded England’s lowest proportion of stage I/II lung cancer diagnoses at presentation, at 23%. The lung cancer screening programme (LCS) began as a pilot in one locality in 2021 and expanded to another in 2022, before becoming part of the current national screening programme. We evaluated the effectiveness of LCS in improving early lung cancer detection and increasing curative treatment by analysing longitudinal trends in stage at diagnosis and treatment received. Methods Data were obtained from the Trust Lung Cancer Database and the LCS Database. Missing information was retrieved from clinic letters and MDT outcomes. Staging data from 2021 onwards were compared with 2019 as the pre-LCS, pre-COVID baseline. The contribution of LCS to early-stage diagnosis was analysed. Treatment received was compared between 2019 and 2025, after four years of programme implementation. Results Early-stage lung cancer detection was 27% in 2019. This increased to 35% in 2021, 42% in 2022, 36% in 2023 and 43% in 2024, and 36.5% in 2025. To date, LCS has diagnosed 356 lung cancers, of which 280 (78.7%) were stage I/II and 279 (78.4%) received curative treatment. The contribution of LCS to all stage I/II cancers was 20% in 2021, 54% in 2022, 39% in 2023, 23% in 2024 and 30% in 2025.The proportion of all patients receiving curative treatment increased from 23% in 2019 to 33.2% in 2025. In 2025, 165 patients, representing 36.7% of all lung cancers, were retrospectively identified as LCS-eligible but had missed the opportunity to participate because of non-registration, non-contact or non-engagement. Conclusions Four years after implementation of LCS, the proportion of lung cancers detected at stage I/II increased by 9.7%, with a similar 10% increase in patients receiving curative treatment. This improvement has been sustained over five years compared with pre-LCS data. Improving registration data, contact processes and engagement is likely to sustain and strengthen this shift towards earlier diagnosis and curative treatment.
Source: Thorax
Language: English
Field: Medicine
Open Access status: bronze
OpenAlex ID: W7225188441
Cites:
Cited by:
Related to: 10